The Growing Burden of Neuropathic Pain Worldwide

Neuropathic pain, a debilitating condition arising from damage or dysfunction in the somatosensory nervous system, affects millions globally, manifesting as burning sensations, shooting pains, or heightened sensitivity to touch and cold. Unlike typical inflammatory pain, it persists long after the initial injury, severely impacting quality of life, work productivity, and mental health. Recent estimates indicate that neuropathic pain impacts between 580 and 830 million people worldwide, underscoring its status as a major public health challenge. In the United States alone, prevalence rates hover around 9.8% among adults, while Europe sees varying figures influenced by aging populations and chronic diseases like diabetes and multiple sclerosis.

This form of chronic pain often stems from conditions such as diabetic neuropathy, chemotherapy-induced peripheral neuropathy, post-herpetic neuralgia, or traumatic nerve injuries. Patients frequently describe it as electric shocks or pins and needles that disrupt sleep, daily activities, and emotional well-being. Current treatments, including anticonvulsants like gabapentin or pregabalin, antidepressants, and opioids, provide only partial relief for about 30-50% of individuals, with side effects like drowsiness, weight gain, and addiction risks limiting their use. The unmet need has propelled research into novel targets, particularly within the peripheral nervous system.

Decoding the Genetics of Pain: The Pivotal Role of SCN9A and Nav1.7

At the heart of pain signaling lies the voltage-gated sodium channel Nav1.7, encoded by the SCN9A gene on chromosome 2. This channel, predominantly expressed in nociceptors—specialized sensory neurons that detect harmful stimuli—facilitates the initiation and propagation of action potentials. When activated by stimuli, Nav1.7 opens rapidly, allowing sodium influx that depolarizes the neuron and transmits pain signals to the spinal cord and brain.

Genetic studies over the past two decades have cemented SCN9A's role. Loss-of-function mutations cause congenital insensitivity to pain (CIP), where individuals feel no pain, highlighting Nav1.7's necessity. Conversely, gain-of-function variants lead to extreme pain disorders like primary erythromelalgia or paroxysmal extreme pain disorder. These human monogenic conditions validate Nav1.7 as a prime therapeutic target. Pioneering work from university labs, such as Stephen Waxman's group at Yale School of Medicine, elucidated these mechanisms through patient-derived models and rodent knockouts, laying the academic groundwork for targeted therapies.

However, Nav1.7 shares 70-90% sequence homology with other sodium channels like Nav1.5 in the heart, complicating selective small-molecule inhibition and raising cardiac toxicity concerns in early trials.

Limitations of Conventional Neuropathic Pain Therapies

Standard treatments target downstream pathways but fail to address the root hyperexcitability in nociceptors. Opioids, while effective short-term, contribute to the global crisis with over 100,000 annual overdose deaths in North America alone. Non-opioid options like tricyclic antidepressants or serotonin-norepinephrine reuptake inhibitors help some but often cause cognitive impairment unsuitable for long-term use. Topical agents like capsaicin or lidocaine offer localized relief but not for widespread neuropathy.

Clinical guidelines from bodies like the International Association for the Study of Pain (IASP) emphasize multimodal approaches, yet up to 40% of patients remain refractory. This gap has shifted focus to precision medicine, leveraging genetics for patient stratification and novel interventions.

Genomic Medicine Emerges as a Game-Changer

Genomic medicine, encompassing gene silencing, editing, and replacement, promises durable, non-opioid relief by directly modulating pain genes. Antisense oligonucleotides (ASOs), CRISPR-based tools, and adeno-associated virus (AAV) vectors have shown promise in preclinical models. For SCN9A, early ASO trials like OLP-1002 demonstrated analgesic effects in osteoarthritis pain, paving the way for neuropathy applications.

Zinc finger repressors (ZFRs)—engineered proteins that bind specific DNA sequences to recruit repressive machinery—offer precise transcriptional silencing without cutting DNA, minimizing off-target risks compared to CRISPR nucleases.

Landmark Publication in Science Translational Medicine

A groundbreaking study published on March 25, 2026, in Science Translational Medicine details the first preclinical validation of ZFRs targeting human/primate SCN9A for neuropathic pain. Titled "Engineered zinc finger repressors induce a prolonged and selective repression of SCN9A in nociceptors of nonhuman primates," the research demonstrates robust, long-lasting gene repression in relevant models.Access the full study here. Led by researchers including Toufan Parman and Mohammad Samie from Sangamo Therapeutics, with roots in academic zinc finger technology developed at universities like the University of Utah and UCSD, it bridges bench-to-bedside innovation.

Preclinical Success in Mouse and Nonhuman Primate Models

In the spared nerve injury (SNI) mouse model—mimicking surgical neuropathic pain—intrathecal AAV-delivered ZFRs achieved up to 70% repression of Scn9a in dorsal root ganglia (DRG) nociceptors. This correlated with complete reversal of mechanical and cold allodynia, restoring baseline sensitivity for months post-injection. Single-cell RNA sequencing confirmed nociceptor-specific silencing, sparing motor neurons.

Translating to cynomolgus macaques, AAV9-ST-503 (lead candidate) via lumbar intrathecal infusion yielded 50% SCN9A repression in bulk DRG tissue at six months, with deeper nociceptor-specific effects. No impacts on cardiac function, motor coordination, or histopathology were observed, addressing key safety hurdles.

• 70% Scn9a knockdown in mouse DRG, full pain reversal in SNI.
• 50% SCN9A repression at 6 months in primate DRG.
• Selective nociceptor targeting via single-cell validation.
• Zero dose-limiting toxicities in 6-month NHP study.

Safety, Delivery, and Path to Human Trials

ZFRs' epigenetic mechanism—recruiting HDACs and DNA methyltransferases—ensures stable, non-mutagenic repression. AAV9's tropism for DRG enables one-time dosing, potentially lasting years. Sangamo's ST-503 received FDA Fast Track designation and IND clearance, with Phase 1 trials (NCT06980948) enrolling idiopathic small fiber neuropathy (iSFN) patients—those with refractory burning pain from small nociceptor loss.Learn more about ST-503

Challenges include optimizing dose for humans and monitoring immunogenicity, but primate data bode well.

Academic Foundations and University Contributions

This advance builds on decades of university-led research. Yale's Waxman lab identified Nav1.7's role via SCN9A mutations, while UCSD's 2021 study demonstrated in situ NaV1.7 repression for analgesia. Sangamo's ZFR platform stems from academic pioneers like Carlos Barbas at Scripps Research. Pain research hubs at Johns Hopkins, King's College London, and McGill University continue validating targets through iPSC models and electrophysiology.

For aspiring researchers, opportunities abound in gene therapy labs, electrophysiology, and translational neuroscience, fueling the next wave of innovations.

Global Context: IASP's 2026 Global Year for Neuropathic Pain

Coinciding with the International Association for the Study of Pain's 2026 Global Year theme, this publication amplifies calls for better diagnostics, like skin biopsies for SFN, and equitable access.Explore IASP resources University-led initiatives, from European pain clinics to Asian neuropathy cohorts, provide diverse perspectives on cultural pain expression and treatment disparities.

Future Horizons: Transforming Pain Management

Success of ST-503 could usher in an era of genetic analgesics for chemotherapy neuropathy, diabetic pain, and fibromyalgia. Combination with neuromodulation or AI-driven patient selection may enhance outcomes. Economically, the neuropathic pain market is projected to reach $16.78 billion by 2034, driven by biologics. For patients, a one-time infusion promising years of relief without opioids represents hope. Ongoing trials and academic collaborations will refine this precision paradigm, potentially redefining chronic pain care.

Photo by Benny sun on Unsplash